Sponsored Content
Xorialyc® is a next-generation olive leaf extract (300 mg/day). In a 60-day consumer study with 50 adults (40–60 y), it reduced redness (74%), itching (76%), tightness (72%) and improved skin hydration and quality (~72%). 80% noticed visible effects, 78% said it worked fast and would recommend it. Its activity comes from luteolin, quercetin and ortho-diphenols, which inhibit NF-κB, COX-2 and PGE₂ while providing strong antioxidant protection.
Consumer Study Confirms the Efficacy and Tolerability of Xorialyc® for Sensitive and Irritated Skin
Date: April 9, 2025
Xorialyc®, Pharmactive’s next-generation olive leaf extract, is positioning itself as a premium botanical solution for inflammatory skin concerns such as redness, itching, tightness, and discomfort. While often perceived as only an aesthetic issue, skin inflammation has deeper consequences, directly affecting emotional wellbeing and self-confidence.
Environmental aggressors like pollution, UV exposure, wind, as well as topical irritants and impaired skin barrier function are increasingly linked to skin sensitivity. As a result, the demand for natural, effective, and well-tolerated solutions has never been higher.
Real-World Evidence: 60-Day Consumer Study
To validate Xorialyc®’s effects in daily life, Pharmactive conducted a consumer perception study with 50 healthy adult volunteers (men and women, aged 40–60, average age 48). All participants reported baseline discomforts such as redness, itching, tightness, and irritation, but were not under dermatological treatments or taking other supplements.
Each participant consumed one capsule per day containing 300 mg of Xorialyc®. Outcomes were assessed before and after 60 days using standardized questionnaires.

Key Findings:
- 76% reported reduced itching
- 74% experienced less facial redness and inflammation
- 74% noticed improved skin hydration
- 72% felt reduced skin tightness
- 72% reported overall better skin quality
- 80% observed visible effects
- 78% stated that Xorialyc® works quickly
- 78% would recommend it
- 74% found it more effective than previous products they had tried
These results highlight both the high tolerability and consumer satisfaction, confirming Xorialyc®’s potential as a natural, long-term solution for common skin complaints.
Botanical Science Behind the Results
The efficacy of Xorialyc® lies in its unique composition and standardization:
≥ 0.1 mg/g of luteolin-7-O-glucoside, protocatechuic acid, and quercetin (analyzed by HPLC)
≥ 20% ortho-diphenols (measured by UV)
These bioactive compounds are well-recognized for their antioxidant and anti-inflammatory properties.
In in-vitro studies, Xorialyc® demonstrated that it:
Inhibits the NF-κB pathway, a master regulator of inflammation
Downregulates inflammatory gene expression such as COX-2
Reduces PGE₂ production, a key pro-inflammatory molecule
Shows strong antioxidant capacity, helping to restore balance in skin exposed to oxidative stress
Thanks to this multifaceted mechanism, Xorialyc® works from within to calm and restore sensitive skin, targeting the root causes of inflammation.
Consumer Perception by Gender
The study also revealed distinct consumer expectations:
Women prioritized improvements in skin hydration and overall quality.
Men, often more affected by shaving-related irritation, looked for relief from itching and redness.
These insights can help brands tailor both formulations and marketing strategies to different target audiences.
Natural. Effective. Reliable.
As consumer demand for clean-label, plant-based ingredients backed by science continues to grow, Xorialyc® stands out for its unique positioning:
Derived from Olea europaea L. (olive leaf).
Premium standardization with traceable actives.
Supported by scientific and consumer evidence.
Suitable for nutricosmetics, dermaceuticals, and “beauty-from-within” concepts.
Contact & Further Information
For collaboration opportunities, technical documentation, or free samples: [email protected]
Pharmactive Biotech Products, S.L. is a Spanish company dedicated to developing and manufacturing differentiated, science-backed natural ingredients for the nutraceutical, pharmaceutical, and veterinary industries.
23 Feb 2026
PharmaLinea, a Slovenian developer and manufacturer of private label food supplements, has announced the completion of a clinical study evaluating its finished formulation for iron deficiency.
Read more
12 Feb 2026
Gentle and effective: magnesium bisglycinate is setting a new standard. Through its LomaChelateX® brand, Dr. Paul Lohmann® delivers magnesium bisglycinate and a broad range of fully reacted mineral bisglycinates made in Germany.
Read more
22 Jan 2026
The global leader in fucoidan science, Marinova Pty Ltd, reported record annual fucoidan production for 2025. The company's total production volume has more than doubled over the past three years.
Read more
6 Jan 2026
HYDERABAD, December 20, 2025 – India’s Prime Minister Mr. Narendra Modi, alongside WHO Director-General Dr. Tedros Adhanom Ghebreyesus, released a commemorative postal stamp honoring ashwagandha at the recently concluded Second WHO Global Traditional...
Read more
22 Dec 2025
PharmaLinea held its first-ever NutraLoop™ Summit this December. The virtual event featured 12 speakers from companies such as IQVIA, NHCO, Radicle Science, and BeyondBrands, who provided comprehensive insights across the scientific and commercia...
Read more
11 Dec 2025
Royal FrieslandCampina N.V. intends to acquire Wisconsin Whey Protein, a respected producer of whey protein isolates in the United States. Wisconsin Whey Protein will become part of FrieslandCampina Ingredients, a global leader in proteins and prebioti...
Read more
11 Dec 2025
Kaiseraugst (Switzerland), Maastricht (Netherlands), December 5, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announces ‘Frosted Star Anise’ as its Flavor of the Year for 2026. This...
Read more
11 Dec 2025
Montvale, New Jersey, (10 December, 2025) – Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health, is pleased to announce the development of a new, high-capacity man...
Read more
4 Dec 2025
Marinova has been named Australia's most outstanding contributor to international health in the nation's prestigious Australian Export Awards.
Read more
1 Dec 2025
Prayon inaugurates its new SHMP production unit in Engis, a major investment that strengthens its position in the food and technical phosphates market
Read more